Evaluating the Readability, Quality, and Reliability of Online Patient Education Materials on Spinal Cord Stimulation.

AIM: To obtain health-related information internet usage is rapidly increasing. However, there are concerns about the comprehensibility and reliability of internet-accessed health-related information. The aim of this research was to investigate the reliability, quality, and readability of patient education materials (PEMs) about spinal cord stimulation (SCS) on the internet. MATERIAL AND METHODS: A total of 114 websites suitable for the study were identified after a search on Google for the term "spinal cord stimulation." Gunning Fog (GFOG), Flesch-Kincaid Grade Level (FKGL), Flesch Reading Ease Score (FRES), and Simple Measure of Gobbledygook (SMOG) were used to determine the readability of sites. The credibility of the websites was assessed using the Journal of the American Medical Association (JAMA) score. Quality was assessed using the global quality score (GQS), the DISCERN score, and the Health on the Net Foundation code of conduct (HONcode). RESULTS: Evaluating the text sections, the mean SMOG and FKGL were 10.92 ± 1.61 and 11.62 ± 2.11 years, respectively, and the mean FRES and GFOG were 45.32 ± 10.71 and 14.62 ± 2.24 (both very difficult), respectively. Of all the websites, 10.5% were found to be of high quality, 13.2% were found to be of high reliability, and only 6.1% had a HONcode. A significant difference was found between the typologies of the websites and the reliability and quality scores (p < 0.05). CONCLUSION: The internet-based PEMs about SCS were found to have a readability level that exceeded the Grade 6 level recommended by the National Health Institute. However, the materials demonstrated low reliability and poor quality. It is advisable that websites addressing Spinal Cord Stimulation (SCS), a specific neuromodulation technique among various interventional strategies for chronic pain management, maintain readability standards in line with established indexes and provide content that is reliable and tailored to the general public's educational level.

Dose escalation in intrathecal baclofen therapy based on disease etiology: Can an a priori target dose be established? A ten-year follow-up study.

CONTEXT: Intrathecal baclofen (ITB) therapy is administered for severe, persistent spasticity that cannot be addressed by oral medication or other treatments. OBJECTIVE: We aimed to evaluate the target dose of ITB for severe, persistent spasticity based on disease etiology. METHODS: Data at baseline (discharge), 1, and 10 years from 102 patients who received ITB therapy between 1985 and 2011 were retrospectively collected. Patients were divided based on disease etiology (cerebral, spinal, or multiple sclerosis [MS]) to evaluate differences in dose requirements. A comprehensive literature review of the dose trends in ITB therapy was conducted. RESULTS: Patients with cerebral spasticity (n = 62) required the highest dose after discharge (102.66 ± 30.9 µg), 1 (402.29 ± 300.2 µg), and 10 years (578.74 ± 421.2 µg). Patients with spinal spasticity (n = 19) required an average of 82.89 ± 30.7 µg baclofen at discharge, 296.3 ± 224.6 µg after 1 year, and 522.63 ± 425.97 µg after 10 years. Patients with MS-related spasticity (n = 21) had a dose of 82.73 ± 39.3 µg baclofen at discharge, 226.95 ± 193.3 µg after 1 year, and 320.6 ± 261.4 µg after 10 years. The differences among the categories were significant after 1 and 10 years of therapy. CONCLUSIONS: The largest dose escalation occurs within the first year of ITB therapy. Our work provides a guideline for the initial dose setting during the inpatient stay after implantation and potentially expected dosage over the years thereafter, although this must always be adjusted individually.